StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Earnings

Vir Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
-$188.00K
-194.0% on a year earlier
EPS, Q3 FY2026
-$0.57
-$1.17 a year earlier
Latest guidance
Lowered
Aug 1, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Vir Biotechnology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close-$188.00K-194.0%-$0.57Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$238.90M+19808.3%$0.47Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close-$29.00K-101.0%-$0.85Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$200.00K-91.7%-$1.17Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$1.20M-61.3%–Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$3.00M-94.7%-$0.88Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close$12.40M-26.2%-$0.76Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024after the close$2.40M-7.7%-$1.56Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$3.10M-18.4%-$1.02Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close$56.40M-10.5%-$0.48Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Vir Biotechnology guided for has been reported

Guidance history

Every forecast Vir Biotechnology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 1, 2024GAAP operating expense rangeFY2024$580.00M – $610.00MLowered
May 2, 2024Stock-based compensation expenseFY2024$105.00M – $115.00MNew
May 2, 2024Restructuring chargesFY2024$25.00M – $35.00MLowered
May 2, 2024GAAP combined R&D and SG&A expense rangeFY2024$650.00M – $680.00MRaised
Feb 22, 2024GAAP combined R&D and SG&A expense rangeFY2024$650.00M – $680.00MNew
Feb 22, 2024Stock-based compensation expenseFY2024$105.00M – $115.00MLowered
Feb 22, 2024Restructuring chargesFY2024$25.00M – $35.00MLowered
Feb 24, 2022sotrovimab collaboration revenuesFY2022$1.10BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Vir Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. News
  3. Results
  4. News
  5. News
  6. Update
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. News
  15. Results

See a number that looks wrong?